枸橼酸托法替布治疗活动性强直性脊柱炎的随机对照研究

Effect of tofatib citrate on active ankylosing spondylitis:A randomized controlled study

目的 探讨枸橼酸托法替布治疗活动性强直性脊柱炎(AS)的疗效及安全性。方法 2017年1月至2021年1月间在本院接受治疗的活动性AS患者90例参照随机数表法将其分为对照组、观察组各45例。对照组患者接受活动性AS常规治疗,观察组患者在对照组治疗方案基础上加入枸橼酸托法替布治疗,持续治疗3疗程后评估疗效。对比两组患者的Bath强直性脊柱炎功能指数(BASFI)、Bath强直性脊柱炎计量指数(BASMI)、总体背痛评分、Jenkins睡眠评估问卷调查(JSEQ)评分和外周血C反应蛋白(CRP)、血沉(ESR)水平以及整体疗效分级的差异,记录相关不良反应发生情况。结果 治疗3疗程后,观察组患者的BASFI、BASMI、VAS、JSEQ评分值低于对照组患者(P <0.05);观察组患者的外周血CRP、ESR水平均低于对照组患者(P <0.05);观察组患者的治疗总有效率高于对照组患者(P <0.05)。两组患者的治疗相关不良反应发生情况差异无统计学意义(P> 0.05)。结论 枸橼酸托法替布治疗活动性AS可有效优化病情、提升疗效且具有良好的安全性。

Objective To explore the efficacy and safety of tofatib citrate in the treatment of active ankylost spondylitis(AS). Methods A total of 90 patients with active AS hospitalized in our hospital from January 2017 to January 2021 were included and were equally divided into control group and observation group using the random number table method. The patients in the control group received routine treatment for active AS,and those in the observation group were treated with tofatib citrate in addition to the routine treatment regimen as in the control group,and the efficacy was evaluated after continuous treatment for 3 courses. The two groups were compared in terms of the scores by Bath Ankylosing spondylitis function Index(BASFI),Bath Ankylosing spondylitis measurement Index(BASMI),total back pain scoring and Jenkins Sleep Assessment Questionnaire(JSEQ),the levels of c-reactive protein(CRP)and ESR in peripheral blood,the overall efficacy grades and the occurrence of treatment-related adverse reactions. Results After 3 courses of treatment,the BASFI,BASMI,VAS and JSEQ scores of the observation group were all significantly lower than those of the control group(P < 0.05). The levels of CRP and ESR in the observation group were significantly lower than those in the control group(P < 0.05). The total effective rate in the observation group was significantly higher than that in the control group(P < 0.05). There was no statistical significance in the occurrence of treatment-related adverse reactions between the two groups(P >0.05). Conclusion Tofatib citrate can effectively optimize the condition and improve the efficacy in the treatment of active AS with good safety.